SREBP-1 und Fettleber

详细信息    查看全文

• 作者：D. Müller-Wieland (1) d.mueller-wieland@asklepios.com
  B. Knebel (2)
  J. Haas (1)
  J. Kotzka (2)
• 关键词：Metabolic syndrome – Insulin resistance – Obesity – Fatty liver – Non ; alcoholic fatty liver disease
• 刊名：Herz
• 出版年：2012
• 出版时间：May 2012
• 年：2012
• 卷：37
• 期：3
• 页码：273-280
• 全文大小：414.4 KB
• 参考文献：1. Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 112:2735–2752
  2. Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645
  3. Ludwig J, Viggiano TR, McGill DB et al (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434–438
  4. Donnelly KL, Smith CI, Schwarzenberg SJ et al (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343–1351
  5. Day CP, James OF (1998) Steatohepatitis: a tale of two ?hits“? Gastroenterology 114:842–845
  6. Marchesini G, Bugianesi E, Forlani G et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923
  7. Pagano G, Pacini G, Musso G et al (2002) Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35:367–372
  8. Parekh S, Anania FA (2007) Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132:2191–207
  9. Charlton M, Sreekumar R, Rasmussen D et al (2002) Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35:898–904
  10. Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106:473–481
  11. Rab?l R, Petersen KF, Dufour S et al (2011) Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci U S A 108:13705–13709
  12. Petersen KF, Dufour S, Savage DB et al (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 104:12587–12594
  13. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–1131
  14. Matsumoto M, Han S, Kitamura T et al (2006) Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 116:2464–2472
  15. Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95–96
  16. Cheng Z, White MF (2011) Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal 14:649–661
  17. Knebel B, Haas J, Hartwig S et al (2012) Liver specific expression of transcriptional active SREBP-1c is associated with fatty liver and increase fat mass. PLoS One 7(2):e31812
  18. Kotzka J, Knebel B, Haas J et al (2012) Preventing phosphorylation of sterol regulatory element-binding protein 1a by MAP-kinases protects mice from fatty liver and visceral obesity. PLoS One, 7(2):e32609
  19. Kotzka J, Knebel B, Janssen OE et al (2011) Identification of a gene variant in the master regulator of lipid metabolism SREBP-1 in a family with a novel form of severe combined hypolidaemia. Atherosclerosis 218:134–143
  20. McGarry JD (1992) What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258:766–770
  21. Biddinger SB, Hernandez-Ono A, Rask-Madsen C et al (2008) Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 7:125–134
  22. Unger RH (2002) Lipotoxic diseases. Annu Rev Med 53:19–36
  23. Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331–340
  24. Brown MS, Goldstein JL (1999) A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 96:11041–11048
  25. Kotzka J, Müller-Wieland D (2004) Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert Opin Ther Targets 8:141–149
  26. Tang JJ, Li JG, Qi W et al (2011) Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab 13:44–56
  27. Li Y, Xu S, Mihaylova MM et al (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13:376–388
  28. Look AHEAD Research Group (2010) Long-term effects of a lifestyle intervention on weight in cardiovascular risk factors in individuals with type-2-diabetes mellitus. 4-Year results of the Look AHEAD trial. Arch intern Med 170:1566–1575
  29. Lazo M, Solga SF, Horska A et al (2010) Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type-2-diabetes. Diabetes Care 33:2156–2163
  30. Petersen KF, Dufour S, Befroy D et al (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603–608
  31. Stefan N, Kantarzis K, H?ring HU (2008) Causes and metabolic consequences of Fatty liver. Endocr Rev 29:939–960
  32. Kotronen A, Yki-J?rvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38
  33. World Health Organisation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of WHO consultation. WHO/NCO/NCS/99.2
  34. Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16(5):442–443
  35. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486–2497
  36. Einhorn D, Reaven GM, Cobin RH et al (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252
  37. International Diabetes Federation. Worldwide definition of the metabolic syndrome.available http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf (accessed 2005 Aug 24)
• 作者单位：1. Herz-, Gef??- und Diabeteszentrum u. Abteilung für Allgemeine Innere Medizin, Asklepios Klinik St. Georg, Asklepios Campus Hamburg, Medizinische Fakult?t der Semmelweis-Universit?t, Lohmühlenstr. 5, 20099 Hamburg, Deutschland2. Institut für Klinische Biochemie und Pathobiochemie, Deutsches Diabetes-Zentrum, Leibniz-Institut für Diabetesforschung, Heinrich-Heine-Universit?t, Düsseldorf, Deutschland
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  
• 出版者：Urban & Vogel
• ISSN：1615-6692

文摘

Insulinresistenz und viszerale Fettverteilung spielen in aller Regel bei der Entstehung klinischer Facetten des metabolischen Syndroms (z. B. Dyslipid?mie, Diabetes und Atherosklerose) eine entscheidende Rolle. In dieser übersicht werden einige neuere Zusammenh?nge mit der Fettleber skizziert, für deren Suszeptibilit?t zumindest im Tiermodell die Aktivit?t von Transkriptionsfaktoren in der Leber, wie z. B. von ?sterol regulatory element-binding protein 1“ (SREBP-1), eine entscheidende Rolle spielt. Neben dieser molekularen Betrachtung wird auf therapeutische Lebensstilma?nahmen wie z. B. Gewichtsreduktion eingegangen, die nicht nur mit einer Verbesserung der Insulinsensitivit?t, sondern auch mit Reduktion einer Fettleber assoziiert sind.